Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma

BACKGROUND. Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. METHODS. Using the Nat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Margalit, Ofer, Mamtani, Ronac, Kopetz, Scott, Yang, Yu‐Xiao, Lawrence, Yaacov R., Abu‐Gazala, Samir, Reiss, Kim A., Golan, Talia, Halpern, Naama, Aderka, Dan, Giantonio, Bruce, Shacham‐Shmueli, Einat, Boursi, Ben
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Gastrointestinal Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693732/
https://ncbi.nlm.nih.gov/pubmed/30696723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0333
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items